Pharmaceutical combinations for the treatment of cancer
AssigneePresage Biosciences, Inc.
InventorsRichard KLINGHOFFER, Joyoti DEY
Life of this patent
Estimating the term…
Abstract
The disclosure herein provides combination therapies for the treatment of cancers such as Leukemia, lymphoma and triple negative breast cancer. The disclosure provides combination therapies of CDK inhibitors, e.g., a CDK inhibitor represented by Formula I: or a pharmaceutically acceptable salt thereof together with a BCL-2 inhibitor or proteasome inhibitor for the treatment of cancer.
Claims23
A method of treating a blood cancer comprising administering to a subject in need thereof a therapeutically effective amount of a CDK inhibitor represented by Formula Ib:
- or a pharmaceutically acceptable salt thereof,
- and a therapeutically effective amount of venetoclax or a pharmaceutically acceptable salt thereof.
-17. (canceled)
-48. (canceled)
A pharmaceutical composition comprising a therapeutically effective amount of a CDK inhibitor represented by Formula Ib:
- or a pharmaceutically acceptable salt thereof,
- a therapeutically effective amount of venetoclax or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
-66. (canceled)
A pharmaceutical kit for the treatment of a blood cancer, the kit comprising a therapeutically effective amount of a CDK inhibitor represented by Formula Ib:
- or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of venetoclax or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.